GLP2-T

Teduglutide (ALX-0600) is a 33-amino acid recombinant analog of human glucagon-like peptide-2 (GLP-2), developed by NPS Pharmaceuticals (acquired by Shire in 2015, subsequently merged into Takeda). The peptide features a single amino acid substitution — Gly2→Ala — that confers resistance to N-terminal cleavage by dipeptidyl peptidase-4 (DPP-4), extending the plasma half-life from approximately 7 minutes (native GLP-2) to 2–3 hours, enabling once-daily subcutaneous dosing. [1]

Native GLP-2 is a 33-amino acid peptide produced by enteroendocrine L-cells in the ileum and colon, co-secreted with GLP-1 from the proglucagon precursor in response to nutrient ingestion. GLP-2 is the primary endogenous regulator of intestinal adaptation — promoting mucosal growth, enhancing nutrient absorption, reducing intestinal permeability, and modulating intestinal inflammation. [2]

The discovery that GLP-2 drives intestinal mucosal proliferation was made by Daniel J. Drucker, MD at the Lunenfeld-Tanenbaum Research Institute (Mount Sinai Hospital, Toronto) in 1996, establishing the scientific foundation for teduglutide’s development as the first intestinotrophic therapy. [4]

Teduglutide received FDA approval in December 2012 and EMA approval in August 2012 for treatment of adults with short bowel syndrome (SBS) who are dependent on parenteral support (intravenous nutrition and/or fluids). In 2019, FDA approval was expanded to pediatric patients aged ≥1 year. It is marketed as Gattex® (US) and Revestive® (EU and international markets). [3]

In clinical trials, teduglutide demonstrated the ability to reduce parenteral support (PS) volume by ≥20% in significantly more patients than placebo, with some patients achieving complete independence from intravenous nutrition — a clinically transformative outcome for SBS patients who would otherwise require lifelong parenteral support with its associated risks of catheter-related bloodstream infections, liver disease, and reduced quality of life. [5]

1. GLP-2 Receptor — Target and Signaling

Teduglutide is a selective agonist of the GLP-2 receptor (GLP-2R), a class B (secretin-family) G-protein-coupled receptor. GLP-2R is expressed primarily on intestinal subepithelial myofibroblasts (ISEMFs), enteric neurons, and enteroendocrine cells — notably, not directly on intestinal epithelial cells in most species studied. [2]

2. DPP-4 Resistance — The Gly2→Ala Substitution

Native GLP-2 is rapidly inactivated by DPP-4, which cleaves the His1-Gly2 dipeptide bond at the N-terminus. Replacing Gly2 with alanine (Ala) creates steric hindrance that blocks DPP-4 access while preserving full agonist activity at the GLP-2R. This single substitution transforms the half-life from ~7 minutes to ~2–3 hours in humans — a ~20-fold extension enabling once-daily dosing. [1]

3. Indirect Trophic Mechanism — Paracrine Growth Factors

Because GLP-2R is expressed on ISEMFs rather than directly on crypt epithelial cells, teduglutide’s intestinotrophic effects are indirect — mediated via paracrine release of growth factors: [6]

• Keratinocyte Growth Factor (KGF/FGF-7): Stimulates crypt cell proliferation and goblet cell differentiation
• Insulin-like Growth Factor-1 (IGF-1): Promotes enterocyte growth and anti-apoptotic signaling via PI3K/Akt
• Epidermal Growth Factor (EGF): Enhances epithelial restitution and wound healing
• Vasoactive Intestinal Peptide (VIP): Mediates vasodilatory effects on mesenteric blood flow

4. Downstream Effects on Intestinal Morphology

In human clinical studies with teduglutide, intestinal biopsies demonstrated significant increases in villus height (up to 50–60% increase), crypt depth, and mitotic index in both jejunum and ileum after 24 weeks of treatment. [7] These morphological changes directly translate to increased absorptive surface area, as each villus is lined with nutrient-transporting enterocytes. The net result is enhanced absorption of macronutrients, electrolytes, and fluids — the functional basis for reducing parenteral support requirements.

5. Pharmacokinetics

After subcutaneous injection of 0.05 mg/kg/day (the approved dose), teduglutide reaches C_max of ~12–21 ng/mL at T_max of 3–5 hours, with an elimination half-life of approximately 2 hours. Despite the short half-life, the trophic effects accumulate over weeks of daily dosing because intestinal mucosal growth is a cumulative structural process. [8] Teduglutide is primarily cleared via renal elimination of proteolytic fragments; dose reduction is recommended in moderate-to-severe renal impairment.

6. Teduglutide vs. Native GLP-2 vs. Other GLP-2 Analogs

🌿 Short Bowel Syndrome (SBS) — Pivotal Clinical Trials

Teduglutide has been most extensively studied in short bowel syndrome (SBS), a malabsorptive condition resulting from massive intestinal resection. In the pivotal Phase III STEPS trial (Study of Teduglutide Effectiveness in Parenteral nutrition-dependent Short bowel syndrome, n=86), teduglutide 0.05 mg/kg/day SC demonstrated a ≥20% reduction in parenteral support volume in 63% of patients vs. 30% placebo at 24 weeks (p=0.002). [5]

The confirmatory STEPS-2 study (n=88, open-label extension up to 2 years) showed that treatment response was sustained and progressive: mean PS volume reductions of 52% at 1 year and 66% at 2 years. Notably, 13% of patients achieved complete enteral autonomy (full weaning from parenteral support) — a clinically transformative outcome. [9]

🧠 Long-Term Efficacy — STEPS-3 and Real-World Data

The STEPS-3 open-label extension study (up to 30 months) confirmed durable efficacy with continued PS volume reductions and no evidence of tachyphylaxis (loss of effect). Real-world registry data from the SUSTAIN registry corroborated clinical trial findings, with sustained reductions in PS volume and frequency across diverse patient populations. [10]

👶 Pediatric SBS

The TED-C13-003 study (n=59, pediatric patients aged 1–17 years) established teduglutide’s efficacy and safety in pediatric SBS. At 24 weeks, 54% of teduglutide-treated patients achieved ≥20% reduction in PS volume vs. 23% in the standard-of-care group. The safety profile in children was consistent with that observed in adults. FDA pediatric approval followed in 2019. [11]

🫁 Intestinal Failure-Associated Liver Disease (IFALD)

Post-hoc analyses from clinical trials and case series suggest that teduglutide-mediated PS reduction may improve IFALD biomarkers (ALT, AST, bilirubin) by reducing the hepatotoxic burden of parenteral nutrition. Reducing PS volume decreases the lipid emulsion and glucose load delivered intravenously, which are major contributors to PN-associated liver injury. [12]

🔬 Intestinal Mucosal Biology Research

Beyond its clinical indication, teduglutide serves as a critical pharmacological tool compound in intestinal biology research. It is used to study GLP-2R signaling, intestinal stem cell biology, and mucosal adaptation mechanisms. Preclinical research has demonstrated teduglutide’s effects on: [6]

• Intestinal stem cell proliferation and Lgr5+ cell expansion
• Goblet cell differentiation and mucus barrier production
• Mesenteric blood flow regulation
• Intestinal barrier integrity and tight junction protein expression
• Anti-inflammatory effects via suppression of intestinal TNF-α and IL-1β

🔬 Crohn’s Disease and Inflammatory Bowel Disease (Preclinical)

GLP-2R agonism has been explored in preclinical models of Crohn’s disease and IBD. In murine colitis models (DSS and TNBS), GLP-2 analogs reduced mucosal inflammation, decreased intestinal permeability, and accelerated mucosal healing. [13] These findings have not yet progressed to clinical trials for IBD indications.

Key Clinical Studies

Research Dosing Reference (Approved Label Data)

Safety Profile (Pooled Clinical Data)